LOP628 / Novartis - LARVOL DELTA

Targeting KIT in chromophobe renal cell carcinoma (AACR 2025) - "Despite the high KIT expression, knockdown of KIT or treatment with Imatinib, a tyrosine kinase inhibitor that targets KIT, did not decrease the proliferation of ChRCC-derived cells. KIT and its ligand SCF are highly expressed by ChRCC cells and LOP628, a KIT ADC, decreases ChRCC cell proliferation."

Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma. (PubMed, Clin Genitourin Cancer) - "Together, these data demonstrate that KIT is a viable therapeutic target for antibody-drug conjugates in ChRCC, providing a foundation for further investigation into KIT-targeted therapies."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies. (PubMed, Clin Cancer Res) - "Our data suggests LOP628-mediated mast cell degranulation is the likely cause of HSR observed in the clinic due to co-engagement of the FcγR and KIT, resulting in mast cell activation."

Adverse events • Biomarker • Journal

Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody Drug Conjugate against Mutant and Wild Type c-KIT Positive Solid Tumors. (PubMed, Clin Cancer Res) - "The preclinical findings suggest that the c-KIT directed ADC may be a promising therapeutic for the treatment of mutant and wildtype c-KIT positive cancers and supported the clinical evaluation of LOP628 in GIST, AML and SCLC patients."

Journal • Preclinical